aTyr Pharma, Inc. (ATYR) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
aTyr Pharma, Inc. (ATYR) trades at $0.503 with AI Score 16/100 (Grade F). aTyr Pharma, Inc. is a biotherapeutics company focused on discovering and developing medicines based on novel immunological pathways. Market cap: $49.3M, Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: May 7, 2026Analyst Coverage for ATYR: ATYR does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates ATYR against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
ATYR: 3/3 scored disciplines lean bearish. Dominant signal: Seth Klarman bearish.
How is this calculated? →Why this analysis is different
- A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
aTyr Pharma, Inc. (ATYR) Healthcare & Pipeline Overview
aTyr Pharma, Inc. is a biotherapeutics company specializing in the discovery and development of medicines targeting novel immunological pathways. Their lead candidate, efzofitimod, is undergoing Phase III trials for pulmonary sarcoidosis and Phase 1b/2a trials for other interstitial lung diseases, positioning them within the competitive biotechnology sector.
What Is the Investment Thesis for ATYR?
aTyr Pharma's investment thesis centers on the potential of efzofitimod to address unmet needs in pulmonary sarcoidosis and other ILDs. The Phase III clinical trial for pulmonary sarcoidosis represents a near-term catalyst, with positive data potentially driving significant value. The company's pipeline of preclinical programs, including ATYR0101 and ATYR0750, offers longer-term growth opportunities in fibrosis and liver disorders. However, the company's negative profit margin of -39009.5% and gross margin of -11754.7% highlight the significant financial risks associated with biotechnology companies, particularly those in the clinical development stage. Successful commercialization of efzofitimod and advancement of the preclinical pipeline are critical for long-term value creation.
Based on FMP financials and quantitative analysis
ATYR Key Highlights
aTyr Pharma's lead therapeutic candidate, efzofitimod, is in Phase III clinical trial for pulmonary sarcoidosis.
- The company has a collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan.
- aTyr Pharma is developing ATYR0101, a fusion protein, for the treatment of fibrosis, currently in preclinical development.
- The company's market capitalization is approximately $0.08 billion as of May 7, 2026.
- aTyr Pharma's beta of 0.56 indicates lower volatility compared to the overall market.
Who Are ATYR's Competitors?
ATYR is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ORMP Oramed Pharmaceuticals Inc. | $4.79 | +0.00% | $196M | 77 |
| CGEN Compugen Ltd. | $2.65 | +8.61% | $251M | 76 |
| NAGE Niagen Bioscience Inc | $3.15 | -0.63% | $251M | 74 |
| ADAPY Adaptimmune Therapeutics plc | $0.03 | +0.00% | $7.16M | 72 |
| ADGI Adagio Therapeutics, Inc. | $4.64 | +0.87% | $506M | 71 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are ATYR's Key Strengths?
Novel tRNA synthetase biology platform.
- Lead therapeutic candidate, efzofitimod, in Phase III clinical trial.
- Collaboration agreement with Kyorin Pharmaceutical Co., Ltd.
- Focus on unmet needs in severe respiratory diseases and other immune-mediated conditions.
What Are ATYR's Weaknesses?
Negative profit margin and gross margin.
- Reliance on the success of efzofitimod.
- Limited financial resources compared to larger pharmaceutical companies.
- Preclinical programs are early stage and high risk.
What Could Drive ATYR Stock Higher?
Data readout from Phase III clinical trial of efzofitimod for pulmonary sarcoidosis.
- Initiation of Phase III clinical trials for efzofitimod in other interstitial lung diseases (ILDs).
- IND filing for ATYR0101 for the treatment of fibrosis.
- Continued enrollment and progress in Phase 1b/2a clinical trials for efzofitimod in other ILDs.
What Are the Key Risks for ATYR?
Financial-distress signal — its Altman Z-Score of -13.16 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-99.9%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Failure of efzofitimod in Phase III clinical trial.
- Competition from other pharmaceutical companies developing therapies for pulmonary sarcoidosis and other ILDs.
- Regulatory hurdles and delays in obtaining FDA approval.
- Difficulty in raising capital to fund research and development.
- High cash burn rate due to ongoing clinical trials and research activities.
What Are the Growth Opportunities for ATYR?
- Growth opportunity 1: Successful completion of the Phase III clinical trial for efzofitimod in pulmonary sarcoidosis represents a significant growth opportunity. Positive trial results could lead to regulatory approval and commercialization, addressing a market with substantial unmet need. Timeline: Anticipated data readout within the next 12-18 months.
- Growth opportunity 2: Expansion of efzofitimod's clinical development into other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease-related ILD, offers another avenue for growth. These ILDs represent distinct patient populations with limited treatment options, providing aTyr Pharma with the opportunity to address additional unmet needs and expand its market reach. The ILD market is estimated to be worth billions of dollars globally. Timeline: Ongoing Phase 1b/2a trials with potential for Phase III initiation in 2027.
- Growth opportunity 3: Advancement of the preclinical pipeline, including ATYR0101 for fibrosis and ATYR0750 for liver disorders, represents a longer-term growth opportunity. These programs target large and growing markets with significant unmet needs. Successful development and commercialization of these therapies could diversify aTyr Pharma's product portfolio and revenue streams. The fibrosis and liver disease markets are each estimated to be multi-billion dollar markets. Timeline: IND filing for ATYR0101 anticipated in 2028.
- Growth opportunity 4: Leveraging the collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for efzofitimod in Japan provides aTyr Pharma with access to the Japanese market, one of the largest pharmaceutical markets in the world. This partnership allows aTyr Pharma to benefit from Kyorin's local expertise and infrastructure, accelerating the commercialization of efzofitimod in Japan. The Japanese ILD market is a significant portion of the global market. Timeline: Commercialization in Japan contingent on regulatory approval, expected post-Phase III success.
- Growth opportunity 5: Exploring new therapeutic applications of tRNA synthetase biology beyond respiratory and liver diseases represents a longer-term growth opportunity. aTyr Pharma's expertise in this area could lead to the discovery and development of novel therapies for other immune-mediated conditions, expanding the company's pipeline and market reach. This could include autoimmune diseases or other inflammatory conditions. Timeline: Ongoing research and development with potential for new program initiation in 2029.
What Are ATYR's Competitive Advantages?
- Proprietary tRNA synthetase biology platform for discovering novel therapeutic targets.
- Patent protection for efzofitimod and other drug candidates.
- Clinical data supporting the safety and efficacy of efzofitimod.
- Collaboration agreement with Kyorin Pharmaceutical Co., Ltd. provides access to the Japanese market.
What Does ATYR Do?
aTyr Pharma, Inc., founded in 2005 and headquartered in San Diego, California, is a biotherapeutics company focused on the discovery and development of innovative medicines based on novel immunological pathways. The company's primary focus is on addressing unmet needs in severe respiratory diseases and other immune-mediated conditions. Their lead therapeutic candidate, efzofitimod, a selective modulator of NRP2 (neuropilin-2), is currently in Phase III clinical development for pulmonary sarcoidosis, a chronic inflammatory disease affecting the lungs. Additionally, efzofitimod is in Phase 1b/2a clinical trials for the treatment of other interstitial lung diseases (ILDs), including chronic hypersensitivity pneumonitis and connective tissue disease-related ILD. aTyr Pharma is also advancing a pipeline of preclinical programs, including ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase, which is being developed for the treatment of fibrosis. Another preclinical asset, ATYR0750, a domain of alanyl-tRNA synthetase, is being explored for the treatment of liver disorders. The company's approach leverages its expertise in tRNA synthetase biology to develop novel therapies that modulate immune cell function and address the underlying causes of disease. aTyr Pharma has a collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan, expanding its geographic reach and potential market opportunities. The company operates with a team of 56 employees, focusing on research, development, and clinical advancement of its therapeutic candidates.
What Products and Services Does ATYR Offer?
- Discovers and develops medicines based on novel immunological pathways.
- Focuses on severe respiratory diseases and other immune-mediated conditions.
- Develops efzofitimod, a selective modulator of NRP2, for pulmonary sarcoidosis and other interstitial lung diseases (ILDs).
- Advances preclinical programs, including ATYR0101 for fibrosis and ATYR0750 for liver disorders.
- Collaborates with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod in Japan.
- Leverages tRNA synthetase biology to develop novel therapies that modulate immune cell function.
How Does ATYR Make Money?
- Develops and patents novel therapeutic candidates.
- Conducts preclinical and clinical trials to evaluate the safety and efficacy of its drug candidates.
- Seeks regulatory approval from agencies like the FDA for commercialization.
- Out-licenses or partners with other pharmaceutical companies for commercialization and distribution, as seen with Kyorin Pharmaceutical.
What Industry Does ATYR Operate In?
aTyr Pharma operates within the biotechnology industry, a sector characterized by high innovation, significant regulatory hurdles, and substantial financial risk. The market for pulmonary sarcoidosis and other interstitial lung diseases is substantial and growing, driven by an aging population and increasing prevalence of these conditions. Competition includes established pharmaceutical companies and other biotechnology firms developing therapies for respiratory and immune-mediated diseases. aTyr Pharma's focus on tRNA synthetase biology and novel immunological pathways differentiates it from some competitors, but the company faces challenges in securing regulatory approval and commercializing its products.
Who Are ATYR's Key Customers?
- Patients suffering from pulmonary sarcoidosis and other interstitial lung diseases (ILDs).
- Patients with fibrosis.
- Patients with liver disorders.
- Pharmaceutical companies through licensing and collaboration agreements.
Company Profile
aTyr Pharma, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in San Diego, United States.
Financial Health
aTyr Pharma, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -13.16 places it in the distress zone, a signal of elevated financial risk.
Key Financial Metrics
Return on equity for aTyr Pharma, Inc. stands at -99.9%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -87.9%, showing how much profit it generates from its asset base. A current ratio of 5.78 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -156.8%, the inverse of the P/E and a quick read on earnings relative to price.
ATYR Valuation & Market Position
With a $49.3M market cap, aTyr Pharma, Inc. sits in the micro-cap segment of the market. Relative to its peer group, ATYR's quantitative score of 16/100 is below the peer average of 76/100.
Forward Outlook
Wall Street analysts project aTyr Pharma, Inc. revenue of about $3.9M for fiscal 2026, with EPS near $-0.56. The estimate reflects 6 contributing analysts.
ATYR Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in aTyr's pipeline, indicating that key stakeholders believe in the company's potential.
- Community sentiment has shifted positively as discussions around their innovative therapies gain traction, reflecting growing interest.
- Recent announcements about potential partnerships have sparked excitement, with many seeing these as validation of aTyr's research efforts.
- The company's focus on rare diseases aligns with a growing market trend, attracting attention from investors looking for niche opportunities.
Bear Case
- Despite recent positive sentiment, there's lingering skepticism about the long timelines often associated with drug development, which could deter some investors.
- Market perception remains cautious due to previous volatility in biotech stocks, leading to hesitance among potential new investors.
- Some community members express concerns about competition in the rare disease space, fearing that aTyr may struggle to differentiate its offerings.
- Recent discussions highlight uncertainty around regulatory approvals, which could impact timelines and investor confidence moving forward.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $190,000 | -$26M | -$0.26 |
Based on FMP financials and quantitative analysis
ATYR Latest News
No recent news available for ATYR.
ATYR Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ATYR.
Price Targets
Wall Street price target analysis for ATYR.
ATYR MoonshotScore
What does this score mean?
The MoonshotScore rates ATYR 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Sanjay S. Shukla
CEO
Sanjay S. Shukla serves as the CEO of aTyr Pharma, bringing extensive experience in the biopharmaceutical industry. His background includes leadership roles in various companies, focusing on strategic development, clinical operations, and commercialization. He has a proven track record of driving growth and innovation in the healthcare sector. His expertise spans across multiple therapeutic areas, including respiratory diseases and immunology. He is responsible for managing a team of 56 employees.
Track Record: Under Sanjay S. Shukla's leadership, aTyr Pharma has advanced efzofitimod into Phase III clinical trials for pulmonary sarcoidosis and expanded its clinical development into other ILDs. He has also overseen the progression of preclinical programs, including ATYR0101 and ATYR0750. He has successfully secured a collaboration agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod in Japan.
Common Questions About ATYR (Healthcare)
What does the AI Score mean for ATYR?
ATYR holds an AI Score of 16/100 (Grade: F). This is an educational research signal, not a buy or sell recommendation. aTyr Pharma, Inc. is a biotherapeutics company focused on discovering and developing medicines based on novel immunological pathways. Their lead therapeutic candidate is efzofitimod, currently …
What does aTyr Pharma, Inc. do?
aTyr Pharma, Inc. is a biotherapeutics company dedicated to discovering and developing novel medicines based on immunological pathways. The company's primary focus is on addressing unmet needs in severe respiratory diseases and other immune-mediated conditions. Their lead therapeutic candidate, efzofitimod, is currently in Phase III clinical development for pulmonary sarcoidosis and Phase 1b/2a trials for other interstitial lung diseases (ILDs).
What do analysts say about ATYR stock?
Analyst coverage of aTyr Pharma is limited, reflecting the company's small market capitalization and early stage of development. General sentiment suggests that the success of efzofitimod in Phase III clinical trials is critical for the company's future. Valuation metrics are difficult to assess given the company's negative profit margin and reliance on future product approvals.
What are the main risks for ATYR?
The main risks for aTyr Pharma include the potential failure of efzofitimod in Phase III clinical trials, competition from other pharmaceutical companies, regulatory hurdles and delays in obtaining FDA approval, and difficulty in raising capital to fund research and development. The company's high cash burn rate and reliance on the success of a single drug candidate also represent significant risks.
What are the key factors to evaluate for ATYR?
aTyr Pharma, Inc. (ATYR) holds an AI score of 16/100 (low). aTyr Pharma's investment thesis centers on the potential of efzofitimod to address unmet needs in pulmonary sarcoidosis and other ILDs. Not financial advice.
How frequently does ATYR data refresh on this page?
ATYR's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven ATYR's recent stock price performance?
aTyr Pharma, Inc. (ATYR) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Novel tRNA synthetase biology platform. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ATYR overvalued or undervalued right now?
aTyr Pharma, Inc. (ATYR) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research ATYR before investing?
Before investing in aTyr Pharma, Inc. (ATYR), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on publicly available sources and may be subject to change.
- Financial data is limited and may not be fully comprehensive.